---
title: "Mustang Bio sells fixed assets to AbbVie for $1.0 million and exits Worcester"
url: "https://aibio.space/news/mustang-bio-sells-fixed-assets-abbvie-1-0-million-exits-worcester/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-02-27"
section: "Mergers"
tickers: "NASDAQ:MBIO"
source: "https://www.sec.gov/Archives/edgar/data/1680048/000110465925018299/tm257773d1_ex99-1.htm"
summary: "The company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts."
---

By the aibio.space news desk.

Sources

- [Mustang Bio, Inc. 8-K (2025-02-27)](https://www.sec.gov/Archives/edgar/data/1680048/000110465925018299/tm257773d1_ex99-1.htm)

[MBIO](https://aibio.space/companies/mustang-bio/)

2025-02-27

# Mustang Bio sells fixed assets to AbbVie for $1.0 million and exits Worcester facility

Tickers [MBIO](https://aibio.space/companies/mustang-bio/)

The company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts.

## Key facts

- **Company**: Mustang Bio, Inc. (NASDAQ: MBIO)

- **News type**: Mergers

- **Primary source**: [Mustang Bio, Inc. 8-K (2025-02-27)](https://www.sec.gov/Archives/edgar/data/1680048/000110465925018299/tm257773d1_ex99-1.htm)

*Planning on a whiteboard. Photo: Startup Stock Photos, CC0, via StockSnap. The picture shows the field, not the companies named.*

Mustang Bio, Inc. (Nasdaq: [MBIO](https://aibio.space/companies/mustang-bio/)) said on February 27, 2025 that it exited the lease for its manufacturing facility in Worcester, Massachusetts. It also sold certain fixed assets, including furniture and equipment, to AbbVie Bioresearch Center Inc. for $1.0 million.

According to the [press release](https://www.sec.gov/Archives/edgar/data/1680048/000110465925018299/tm257773d1_ex99-1.htm) filed with an 8-K, Mustang expects to save approximately $2.0 million of cash expenses tied to the lease over the next 24 months. The company has moved its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts.

Without its own plant, Mustang expects to rely on academic partners and future contract manufacturing relationships to support clinical trials.

The company said it remains focused on its existing portfolio. It expects to support and start a new clinical trial in the second half of 2025 with MB-109 for recurrent glioblastoma and high-grade astrocytomas.

Among the risks it lists, Mustang cites its need for substantial additional funds in the immediate future.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

MBIO

Mustang Bio, Inc.

NASDAQ · United States

Open the starter desk

## More in Mergers

Mergers

### [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/)

Oct 27, 2026

Mergers

### [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/)

Oct 26, 2026

Mergers

### [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/)

Oct 26, 2026

---
Source page: https://aibio.space/news/mustang-bio-sells-fixed-assets-abbvie-1-0-million-exits-worcester/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Mustang Bio sells fixed assets to AbbVie for $1.0 million and exits Worcester", 2025-02-27, https://aibio.space/news/mustang-bio-sells-fixed-assets-abbvie-1-0-million-exits-worcester/